WH Buys More Of GSK’s, AstraZeneca’s COVID Drugs As Omicron Surges

The U.S. government has purchased an additional 600,000 doses of GlaxoSmithKline’s monoclonal antibody for COVID-19, sotrovimab, and plans to purchase another half a million doses of AstraZeneca’s long-acting antibody, Evusheld, for immunocompromised patients, coming amid a surge of COVID-19 cases in the United States caused primarily by the Omicron variant, White House officials announced Wednesday (Jan. 12). HHS has said it believes several of the currently authorized monoclonal antibodies for mild-to-moderate COVID-19 likely won’t work against Omicron -- the exception...